Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis

Journal of Controlled Release

Volumn 188, Issue , 2014, Pages 9-17

  Moulari, Brice ^a   Béduneau, Arnaud ^a   Pellequer, Yann ^a   Lamprecht, Alf ^a,b  

^a France   (France)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Colon targeting; Lectin conjugated nanoparticles; Lectins; Peanut agglutinin; Targeted nanoparticles

Indexed keywords

ADHESION; CELL CULTURE; DISEASES; DRUG DELIVERY; HISTOLOGY; HORMONES; NANOPARTICLES; ORGANIC POLYMERS; PROTEINS; TISSUE;

COLON TARGETING; DRUG LOADED NANOPARTICLE; GASTROINTESTINAL TRACT; INFLAMMATORY BOWEL DISEASE; LECTINS; PEANUT AGGLUTININ; TARGETED NANOPARTICLE; THERAPEUTIC EFFICIENCY;

TISSUE ENGINEERING;

BETAMETHASONE; LECTIN; MYELOPEROXIDASE; NANOPARTICLE; PEANUT AGGLUTININ; TUMOR NECROSIS FACTOR ALPHA; WHEAT GERM AGGLUTININ; DRUG CARRIER; GLUCOCORTICOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL ADHESION; CELL CULTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; DRUG CONJUGATION; DRUG FORMULATION; ENZYMATIC DEGRADATION; EXPERIMENTAL COLITIS; INTESTINE; MALE; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SURFACE PROPERTY; ANIMAL; BINDING SITE; CHEMISTRY; COLITIS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; LARGE INTESTINE; METABOLISM; PATHOLOGY;

ANIMALS; BINDING SITES; COLITIS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GLUCOCORTICOIDS; INTESTINE, LARGE; MALE; MICE; NANOPARTICLES; PEANUT AGGLUTININ; WHEAT GERM AGGLUTININS;

EID: 84903199454     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.05.046     Document Type: Article

References (47)

1. M. Rodriguez, J.A. Antunez, C. Taboada, B. Seijo, and D. Torres Colon-specific delivery of budesonide from microencapsulated cellulosic cores: evaluation of the efficacy against colonic inflammation in rats J. Pharm. Pharmacol. 53 2001 1207 1215 (Pubitemid 32904015)
2. Y. Meissner, and A. Lamprecht Alternative drug delivery approaches for the therapy of inflammatory bowel disease J. Pharm. Sci. 97 2008 2878 2891
3. D.R. Friend New oral delivery systems for treatment of inflammatory bowel disease Adv. Drug Deliv. Rev. 57 2005 247 265 (Pubitemid 39536101)
4. A. Lamprecht Multiparticulate systems in the treatment of inflammatory bowel disease Curr. Drug Targets Inflamm. Allergy 2 2003 137 144
5. H. Nakase, K. Okazaki, Y. Tabata, S. Uose, M. Ohana, K. Uchida, T. Nishi, A. Debreceni, T. Itoh, C. Kawanami, M. Iwano, Y. Ikada, and T. Chiba An oral drug delivery system targeting immune-regulating cells ameliorates mucosal injury in trinitrobenzene sulfonic acid-induced colitis J. Pharmacol. Exp. Ther. 297 2001 1122 1128 (Pubitemid 32472512)
6. A. Lamprecht, N. Ubrich, H. Yamamoto, U. Schafer, H. Takeuchi, P. Maincent, Y. Kawashima, and C.M. Lehr Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease J. Pharmacol. Exp. Ther. 299 2001 775 781
7. A. Lamprecht IBD: selective nanoparticle adhesion can enhance colitis therapy Nat. Rev. Gastroenterol. Hepatol. 7 2010 311 312
8. H. Laroui, G. Dalmasso, H.T. Nguyen, Y. Yan, S.V. Sitaraman, and D. Merlin Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model Gastroenterology 138 2010 843 853 (e841-842)
9. A. Lamprecht, U. Schafer, and C.M. Lehr Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa Pharm. Res. 18 2001 788 793 (Pubitemid 32783514)
10. A. Lamprecht, H. Yamamoto, H. Takeuchi, and Y. Kawashima Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats J. Pharmacol. Exp. Ther. 315 2005 196 202 (Pubitemid 41380512)
11. H. Nakase, K. Okazaki, Y. Tabata, S. Uose, M. Ohana, K. Uchida, Y. Matsushima, C. Kawanami, C. Oshima, Y. Ikada, and T. Chiba Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy J. Pharmacol. Exp. Ther. 292 2000 15 21 (Pubitemid 30026351)
12. S. Hassani, Y. Pellequer, and A. Lamprecht Selective adhesion of nanoparticles to inflamed tissue in gastric ulcers Pharm. Res. 26 2009 1149 1154
13. H. Maeda Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects Bioconjug. Chem. 21 2010 797 802
14. J.D. Byrne, T. Betancourt, and L. Brannon-Peppas Active targeting schemes for nanoparticle systems in cancer therapeutics Adv. Drug Deliv. Rev. 60 2008 1615 1626
15. E. Mahon, A. Salvati, F. Baldelli Bombelli, I. Lynch, and K.A. Dawson Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery" J. Control. Release 161 2012 164 174
16. H. Kouchakzadeh, S.A. Shojaosadati, F. Tahmasebi, and F. Shokri Optimization of an anti-HER2 monoclonal antibody targeted delivery system using PEGylated human serum albumin nanoparticles Int. J. Pharm. 447 2013 62 69
17. S.D. Ryder, M.R. Jacyna, A.J. Levi, P.M. Rizzi, and J.M. Rhodes Peanut ingestion increases rectal proliferation in individuals with mucosal expression of peanut lectin receptor Gastroenterology 114 1998 44 49 (Pubitemid 28020953)
18. Gabor Lectin-mediated bioadhesion: proteolytic stability and binding characteristics of wheat germ agglutinin and solanum tuberosum lectin on Caco-2, HT-29 and human colonocytes J. Control. Release 1997 27 37 (Pubitemid 27417898)
19. A. Weissenbock, M. Wirth, and F. Gabor WGA-grafted PLGA-nanospheres: preparation and association with Caco-2 single cells J. Control. Release 99 2004 383 392 (Pubitemid 39296907)
20. F. Walter, I. Scholl, E. Untersmayr, A. Ellinger, G. Boltz-Nitulescu, O. Scheiner, F. Gabor, and E. Jensen-Jarolim Functionalisation of allergen-loaded microspheres with wheat germ agglutinin for targeting enterocytes Biochem. Biophys. Res. Commun. 315 2004 281 287 (Pubitemid 38183105)
21. Y. Mo, and L.Y. Lim Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate J. Control. Release 107 2005 30 42 (Pubitemid 41253700)
22. B. Rihova, M. Jelinkova, J. Strohalm, M. St'astny, O. Hovorka, D. Plocova, M. Kovar, L. Draberova, and K. Ulbrich Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene Bioconjug. Chem. 11 2000 664 673
23. J.M. Rhodes, R.R. Black, and A. Savage Altered lectin binding by colonic epithelial glycoconjugates in ulcerative colitis and Crohn's disease Dig. Dis. Sci. 33 1988 1359 1363 (Pubitemid 19011526)
24. Y. Shan, L. Wang, Y. Shi, H. Zhang, H. Li, H. Liu, B. Yang, T. Li, X. Fang, and W. Li NHS-mediated QDs-peptide/protein conjugation and its application for cell labeling Talanta 75 2008 1008 1014
25. USP 36 NF 31. United State Pharmacopeia and National Formulary 2013
26. M. Wirth, C. Kneuer, C.M. Lehr, and F. Gabor Lectin-mediated drug delivery: discrimination between cytoadhesion and cytoinvasion and evidence for lysosomal accumulation of wheat germ agglutinin in the Caco-2 model J. Drug Target. 10 2002 439 448 (Pubitemid 35230193)
27. E.R. Smith, P.L. Jones, J.M. Boss, and A.H. Merrill Jr. Changing J774A.1 cells to new medium perturbs multiple signaling pathways, including the modulation of protein kinase C by endogenous sphingoid bases J. Biol. Chem. 272 1997 5640 5646 (Pubitemid 27102391)
28. M.F. Neurath, I. Fuss, B.L. Kelsall, E. Stuber, and W. Strober Antibodies to interleukin 12 abrogate established experimental colitis in mice J. Exp. Med. 182 1995 1281 1290
29. M. Boirivant, I.J. Fuss, A. Chu, and W. Strober Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4 J. Exp. Med. 188 1998 1929 1939 (Pubitemid 28536780)
30. K. Baintner, G. Jakab, Z. Gyori, and P. Kiss Binding of FITC-labelled lectins to the gastrointestinal epithelium of the rat Pathol. Oncol. Res. 6 2000 179 183
31. G. Hartmann, C. Bidlingmaier, B. Siegmund, S. Albrich, J. Schulze, K. Tschoep, A. Eigler, H.A. Lehr, and S. Endres Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice J. Pharmacol. Exp. Ther. 292 2000 22 30 (Pubitemid 30026352)
32. J.E. Krawisz, P. Sharon, and W.F. Stenson Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models Gastroenterology 87 1984 1344 1350 (Pubitemid 15201434)
33. P. Wachsmann, B. Moulari, A. Beduneau, Y. Pellequer, and A. Lamprecht Surfactant-dependence of nanoparticle treatment in murine experimental colitis J. Control. Release 172 2013 62 68
34. W. Niebel, K. Walkenbach, A. Beduneau, Y. Pellequer, and A. Lamprecht Nanoparticle-based clodronate delivery mitigates murine experimental colitis J. Control. Release 160 2012 659 665
35. K. Molin, P. Fredman, and L. Svennerholm Binding specificities of the lectins PNA, WGA and UEA I to polyvinylchloride-adsorbed glycosphingolipids FEBS Lett. 205 1986 51 55 (Pubitemid 16031346)
36. S. Wroblewski, M. Berenson, P. Kopeckova, and J. Kopecek Biorecognition of HPMA copolymer-lectin conjugates as an indicator of differentiation of cell-surface glycoproteins in development, maturation, and diseases of human and rodent gastrointestinal tissues J. Biomed. Mater. Res. 51 2000 329 342 (Pubitemid 30452135)
37. S. Sabri, M. Soler, C. Foa, A. Pierres, A. Benoliel, and P. Bongrand Glycocalyx modulation is a physiological means of regulating cell adhesion J. Cell Sci. 113 Pt 9 2000 1589 1600 (Pubitemid 30312507)
38. R.A. Coapman, and H.S. Cooper Peanut lectin binding sites in human fetal colon Arch. Pathol. Lab. Med. 110 1986 124 127 (Pubitemid 16141848)
39. A. Gebert, and W. Posselt Glycoconjugate expression defines the origin and differentiation pathway of intestinal M-cells J. Histochem. Cytochem. 45 1997 1341 1350 (Pubitemid 27402795)
40. S.P. Vyas, A. Singh, and V. Sihorkar Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting Crit. Rev. Ther. Drug Carrier Syst. 18 2001 1 76 (Pubitemid 32319397)
41. T.F. Orntoft, N. Harving, and N.C. Langkilde O-linked mucin-type glycoproteins in normal and malignant colon mucosa: lack of T-antigen expression and accumulation of Tn and sialosyl-Tn antigens in carcinomas Int. J. Cancer 45 1990 666 672 (Pubitemid 20146126)
42. B.J. Campbell, I.A. Finnie, E.F. Hounsell, and J.M. Rhodes Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin J. Clin. Invest. 95 1995 571 576
43. R.A. Cone Barrier properties of mucus Adv. Drug Deliv. Rev. 61 2009 75 85
44. H.H. Sigurdsson, J. Kirch, and C.M. Lehr Mucus as a barrier to lipophilic drugs Int. J. Pharm. 453 2013 56 64
45. C. Schmidt, C. Lautenschlaeger, E.M. Collnot, M. Schumann, C. Bojarski, J.D. Schulzke, C.M. Lehr, and A. Stallmach Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients J. Control. Release 165 2013 139 145
46. C. Fiocchi Inflammatory bowel disease: etiology and pathogenesis Gastroenterology 115 1998 182 205 (Pubitemid 28307304)
47. Y. Yamada, S. Marshall, R.D. Specian, and M.B. Grisham A comparative analysis of two models of colitis in rats Gastroenterology 102 1992 1524 1534